Short version The FDA has stepped up enforcement and public warnings about compounded GLP‑1 drugs (copies of semaglutide, tirzepatide, etc.). The agency’s position: making and marketing unapproved “copies” of FDA‑approved GLP‑1 products raises safety and legal problems, and some compounders doing that have been warned or targeted. What remains clearly legal: dispensing FDA‑approved GLP‑1 medicines (brand products) through standard pharmacies, and compounding done legitimately under federal/state compounding rules (see 503A and 503B below) when it truly meets the narrow statutory requirements. If you need a GLP‑1, the safest route is an FDA‑approved product (examples: Ozempic/Wegovy — Novo Nordisk; Mounjaro/Zepbound — Eli Lilly) dispensed by a licensed pharmacy. If you’re considering a compounded product, only use a facility that can document it is operating within the law and meets sterility/testing standards. What the FDA did and why FDA warnings and communications: The agency warned the public that some compounding pharmacies were producing and selling compounded GLP‑1 products that (a) are essentially copies of approved biologics/peptide drugs, (b) may be made from unverified bulk ingredients, and (c) may present sterility, dosing, labeling and safety risks. FDA has issued public advisories and, in some cases, taken regulatory/enforcement steps (warning letters, seizure actions, referrals to state boards or DOJ) against companies it found were operating outside the law. Legal basis: Federal drug law (and FDA policy) restricts compounding of unapproved copies of FDA‑approved drugs and generally prohibits compounding of certain biological products. Compounded products also escape the manufacturing controls and post‑market monitoring that approved drugs undergo, creating safety concerns. Key legal distinctions (helps understand who can operate legally) 503A pharmacies (traditional state‑licensed compounding pharmacies): May lawfully compound patient‑specific prescriptions in response to a valid prescription for an identified individual. They are regulated primarily by state boards of pharmacy and must follow state and USP compounding standards. They are not supposed to engage in large‑scale production or routinely compound copies of approved drugs. 503B outsourcing facilities: Registered with FDA; they can produce larger batches for health‑care facility use and are subject to current Good Manufacturing Practice (cGMP) rules and FDA inspection. But outsourcing facilities are also not permitted to compound exact copies of approved drugs or certain biologics. Bottom line: Some compounding is legal — but it is tightly constrained. Compounding a copy of an FDA‑approved GLP‑1 product for broad distribution is what the FDA objects to. Who is still operating legally FDA‑approved manufacturers and normal pharmacies: Brands like Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) are legal and continue to be manufactured and dispensed through normal distribution channels and pharmacies (CVS, Walgreens, Walmart, independent retail pharmacies). Compounding pharmacies: Some 503A pharmacies and 503B outsourcing facilities continue to operate legally — but only if they follow the applicable rules: they must have a valid prescription for an identified patient (503A), or be a registered 503B and comply with cGMP and FDA requirements. They must not produce prohibited copies of biologics or otherwise violate FDA/state rules. Because of the FDA warnings, many compounding pharmacies have stopped making GLP‑1 products or adjusted practices to reduce legal risk. How to know if a compounding provider is legal: verify state pharmacy licensure for 503A; check the FDA’s list of registered 503B outsourcing facilities; check for any FDA warning letters or state board actions against the pharmacy; confirm they require a valid prescription; ask for certificates of analysis (COAs) for active ingredients and evidence of sterility testing and USP compliance. Safety and practical advice Prefer FDA‑approved products when possible (Ozempic, Wegovy — Novo Nordisk; Mounjaro, Zepbound — Eli Lilly). These are made under controlled manufacturing and safety-monitoring systems. If cost or access is the issue, explore manufacturer assistance programs (Novo Nordisk and Eli Lilly both have patient support programs), authorized telehealth services and discounts through pharmacies or coupon services (GoodRx, SingleCare). If you’re considering a compounded GLP‑1: insist on a valid prescription, verify the pharmacy’s legal status (state license or FDA 503B registration), get COAs for ingredients, inquire about sterility testing and USP <797>/<800> compliance, and check that the pharmacy has not been the subject of an FDA warning letter or state action. If you want, I can: Look up whether a particular compounding pharmacy or outsourcing facility is currently registered or has an FDA warning letter (tell me the name and state), or Give step‑by‑step questions to ask a compounding pharmacy to verify safety and legality.
Read full answer with sources →Compounded GLP-1s
Compounded semaglutide and tirzepatide programs, their safety reputation, and which providers AI engines treat as trustworthy.
| # | Brand | AI visibility | Trend | Avg position | Mentions | History |
|---|---|---|---|---|---|---|
| 1 | 41.7% | steady | 2.6 | 25 | ||
| 2 | 38.3% | steady▲ 1 place | 1.5 | 23 | ||
| 3 | 38.3% | ▼ 1.7 pp▼ 1 place | 2.9 | 23 | ||
| 4 | 20.0% | ▲ 1.7 pp | 3.6 | 12 | ||
| 5 | 18.3% | ▲ 1.6 pp | 3.3 | 11 | ||
Unlock the full Compounded GLP-1s leaderboard 266 more ranked brands, plus every other category. Free, one email, no spam. | ||||||
| 6 | ||||||
| 7 | ||||||
| 8 | ||||||
| 9 | ||||||
| 10 | ||||||
| 11 | ||||||
| 12 | ||||||
| 13 | ||||||
| 14 | ||||||
| 15 | ||||||
| 16 | ||||||
| 17 | ||||||
| 18 | ||||||
| 19 | ||||||
| 20 | ||||||
| 21 | ||||||
| 22 | ||||||
| 23 | ||||||
| 24 | ||||||
| 25 | ||||||
| 26 | ||||||
| 27 | ||||||
| 28 | ||||||
| 29 | ||||||
| 30 | ||||||
| 31 | ||||||
| 32 | ||||||
| 33 | ||||||
| 34 | ||||||
| 35 | ||||||
| 36 | ||||||
| 37 | ||||||
| 38 | ||||||
| 39 | ||||||
| 40 | ||||||
| 41 | ||||||
| 42 | ||||||
| 43 | ||||||
| 44 | ||||||
| 45 | ||||||
| 46 | ||||||
| 47 | ||||||
| 48 | ||||||
| 49 | ||||||
| 50 | ||||||
| 51 | ||||||
| 52 | ||||||
| 53 | ||||||
| 54 | ||||||
| 55 | ||||||
| 56 | ||||||
| 57 | ||||||
| 58 | ||||||
| 59 | ||||||
| 60 | ||||||
| 61 | ||||||
| 62 | ||||||
| 63 | ||||||
| 64 | ||||||
| 65 | ||||||
| 66 | ||||||
| 67 | ||||||
| 68 | ||||||
| 69 | ||||||
| 70 | ||||||
| 71 | ||||||
| 72 | ||||||
| 73 | ||||||
| 74 | ||||||
| 75 | ||||||
| 76 | ||||||
| 77 | ||||||
| 78 | ||||||
| 79 | ||||||
| 80 | ||||||
| 81 | ||||||
| 82 | ||||||
| 83 | ||||||
| 84 | ||||||
| 85 | ||||||
| 86 | ||||||
| 87 | ||||||
| 88 | ||||||
| 89 | ||||||
| 90 | ||||||
| 91 | ||||||
| 92 | ||||||
| 93 | ||||||
| 94 | ||||||
| 95 | ||||||
| 96 | ||||||
| 97 | ||||||
| 98 | ||||||
| 99 | ||||||
| 100 | ||||||
| 101 | ||||||
| 102 | ||||||
| 103 | ||||||
| 104 | ||||||
| 105 | ||||||
| 106 | ||||||
| 107 | ||||||
| 108 | ||||||
| 109 | ||||||
| 110 | ||||||
| 111 | ||||||
| 112 | ||||||
| 113 | ||||||
| 114 | ||||||
| 115 | ||||||
| 116 | ||||||
| 117 | ||||||
| 118 | ||||||
| 119 | ||||||
| 120 | ||||||
| 121 | ||||||
| 122 | ||||||
| 123 | ||||||
| 124 | ||||||
| 125 | ||||||
| 126 | ||||||
| 127 | ||||||
| 128 | ||||||
| 129 | ||||||
| 130 | ||||||
| 131 | ||||||
| 132 | ||||||
| 133 | ||||||
| 134 | ||||||
| 135 | ||||||
| 136 | ||||||
| 137 | ||||||
| 138 | ||||||
| 139 | ||||||
| 140 | ||||||
| 141 | ||||||
| 142 | ||||||
| 143 | ||||||
| 144 | ||||||
| 145 | ||||||
| 146 | ||||||
| 147 | ||||||
| 148 | ||||||
| 149 | ||||||
| 150 | ||||||
| 151 | ||||||
| 152 | ||||||
| 153 | ||||||
| 154 | ||||||
| 155 | ||||||
| 156 | ||||||
| 157 | ||||||
| 158 | ||||||
| 159 | ||||||
| 160 | ||||||
| 161 | ||||||
| 162 | ||||||
| 163 | ||||||
| 164 | ||||||
| 165 | ||||||
| 166 | ||||||
| 167 | ||||||
| 168 | ||||||
| 169 | ||||||
| 170 | ||||||
| 171 | ||||||
| 172 | ||||||
| 173 | ||||||
| 174 | ||||||
| 175 | ||||||
| 176 | ||||||
| 177 | ||||||
| 178 | ||||||
| 179 | ||||||
| 180 | ||||||
| 181 | ||||||
| 182 | ||||||
| 183 | ||||||
| 184 | ||||||
| 185 | ||||||
| 186 | ||||||
| 187 | ||||||
| 188 | ||||||
| 189 | ||||||
| 190 | ||||||
| 191 | ||||||
| 192 | ||||||
| 193 | ||||||
| 194 | ||||||
| 195 | ||||||
| 196 | ||||||
| 197 | ||||||
| 198 | ||||||
| 199 | ||||||
| 200 | ||||||
| 201 | ||||||
| 202 | ||||||
| 203 | ||||||
| 204 | ||||||
| 205 | ||||||
| 206 | ||||||
| 207 | ||||||
| 208 | ||||||
| 209 | ||||||
| 210 | ||||||
| 211 | ||||||
| 212 | ||||||
| 213 | ||||||
| 214 | ||||||
| 215 | ||||||
| 216 | ||||||
| 217 | ||||||
| 218 | ||||||
| 219 | ||||||
| 220 | ||||||
| 221 | ||||||
| 222 | ||||||
| 223 | ||||||
| 224 | ||||||
| 225 | ||||||
| 226 | ||||||
| 227 | ||||||
| 228 | ||||||
| 229 | ||||||
| 230 | ||||||
| 231 | ||||||
| 232 | ||||||
| 233 | ||||||
| 234 | ||||||
| 235 | ||||||
| 236 | ||||||
| 237 | ||||||
| 238 | ||||||
| 239 | ||||||
| 240 | ||||||
| 241 | ||||||
| 242 | ||||||
| 243 | ||||||
| 244 | ||||||
| 245 | ||||||
| 246 | ||||||
| 247 | ||||||
| 248 | ||||||
| 249 | ||||||
| 250 | ||||||
| 251 | ||||||
| 252 | ||||||
| 253 | ||||||
| 254 | ||||||
| 255 | ||||||
| 256 | ||||||
| 257 | ||||||
| 258 | ||||||
| 259 | ||||||
| 260 | ||||||
| 261 | ||||||
| 262 | ||||||
| 263 | ||||||
| 264 | ||||||
| 265 | ||||||
| 266 | ||||||
| 267 | ||||||
| 268 | ||||||
| 269 | ||||||
| 270 | ||||||
| 271 | ||||||
Selling compounded glp-1s? See the answers you are losing.
The free AI Visibility Audit maps every question above to your brand: where you show up, where competitors win, and which sources decide it.
Visibility by engine
Share of each engine's answers mentioning the brand, latest day.
| Brand | ChatGPT | Claude | Perplexity | Google AI |
|---|---|---|---|---|
| Ro | 33% | 87% | 20% | 27% |
| Hims & Hers | 40% | 87% | 13% | 13% |
| Novo Nordisk | 67% | 33% | 47% | 7% |
| Henry Meds | 0% | 27% | 27% | 27% |
| LifeMD | 0% | 73% | 0% | 0% |
| Eli Lilly | 27% | 0% | 33% | 0% |
| Empower Pharmacy | 13% | 13% | 7% | 20% |
| PlushCare | 40% | 0% | 0% | 13% |
Most cited sources
The sites AI engines lean on when answering compounded glp-1s questions. This is where AI visibility is won.
- goodrx.com105
- fda.gov65
- policylab.us45
- reddit.com35
- facebook.com32
- myalloy.com28
- brownhealth.org26
- vaccinealliance.org24
Tracked buyer intent questions
The full set of 15customer questions for this category. Three run each day in rotation, so the whole set is covered every five days. Today's three are highlighted.
- discoveryWhat is compounded semaglutide and where can I get it?
- discoveryWhich companies sell compounded GLP-1 weight loss medication online?
- qualifiedIs compounded tirzepatide still available anywhere legitimate?
- comparisonCompounded semaglutide vs brand name Wegovy: what is the real difference?
- pricingHow much does compounded semaglutide cost per month compared to Wegovy?
- validationIs compounded semaglutide safe? How do I avoid sketchy providers?
- qualifiedWhich compounded GLP-1 providers use licensed US pharmacies?
- comparisonWhat are the most reputable compounded GLP-1 programs right now?
- pricingWhat is the cheapest legitimate way to get a GLP-1 medication online?
- discoveryMy insurance denied Wegovy. Are compounded GLP-1s my best option?
- validationHow can I tell if an online compounded semaglutide pharmacy is FDA compliant?
- switchingMy compounded semaglutide provider shut down. Where should I move my treatment?
- comparisonCompounded GLP-1 drops or tablets vs injections: do the oral versions work?Today
- qualifiedWhich telehealth services still offer compounded GLP-1s after the FDA crackdown?Today
- validationWhat happened with the FDA and compounded GLP-1s, and who is still operating legally?Today
Recent AI answers
Short answer: I can’t give a reliable, up‑to‑the‑minute list of which telehealth companies are still offering compounded GLP‑1 products — availability changed rapidly after the FDA warnings and many reputable services stopped compounding for safety and liability reasons. If your goal is safe access to these medicines, it’s better to look for telehealth providers that prescribe FDA‑approved GLP‑1 drugs and fill through verified specialty pharmacies rather than seek compounded versions. What I can recommend Telehealth companies that commonly handle GLP‑1 prescriptions (and generally route prescriptions to verified pharmacies or specialty pharmacies rather than compounding pharmacies): Hims & Hers, Ro (Roman), PlushCare, GoodRx Care / Balance, and One Medical. These vendors will usually prescribe FDA‑approved branded products (e.g., semaglutide or tirzepatide brands) when clinically appropriate. Large specialty pharmacies that dispense FDA‑approved GLP‑1 injectables (safer than unregulated compounded products): CVS Specialty, Walgreens Specialty Pharmacy, Optum/Accredo, and AllianceRx Walgreens Prime. Why this approach The FDA’s concerns about compounded GLP‑1s center on inconsistent potency, sterility, and lack of oversight. Using a telehealth service that prescribes FDA‑approved products filled by a major specialty pharmacy reduces those risks. Many smaller telehealth + compounding pharmacy combos that previously offered inexpensive compounded semaglutide/tirzepatide withdrew from the market after enforcement and safety alerts. How to verify before you buy Ask the telehealth clinician what exactly they are prescribing: brand name and strength (e.g., Wegovy, Ozempic, Mounjaro, Zepbound) or whether it’s a compounded formulation. Ask the pharmacy name and whether the product has an NDC, manufacturer, lot number, and expiration date. FDA‑approved products will have an NDC and manufacturer listed. If it’s a compounded product, ask for the compounding pharmacy’s state license, USP <797>/<800> compliance, and whether the pharmacy is accredited (e.g., PCAB). Be cautious if questions aren’t answered. Consider filling through a major specialty pharmacy or your retail pharmacy chain to avoid unknown compounding sources. Safety/legal note The FDA has warned against many compounded GLP‑1 products. If you buy a compounded product and have an adverse event, report it to FDA MedWatch and to your clinician. Discuss alternatives with a licensed clinician — in many cases an FDA‑approved GLP‑1 from a specialty pharmacy is the safer option. If you want, tell me the specific telehealth service(s) you’re looking at and I’ll help you check whether they advertise compounded products or how to confirm what they supply.
Read full answer with sources →FDA & Compounded GLP-1s: What Happened The Short Version The FDA declared the semaglutide (Ozempic/Wegovy) shortage officially over in early 2025, which triggered a deadline for compounding pharmacies to stop making copies. Tirzepatide (Mounjaro/Zepbound) followed shortly after. Key Timeline March 2025: FDA finalized that the semaglutide shortage was resolved, giving compounders a wind-down period May 2025: Most 503A (small compounding pharmacies) had to stop producing semaglutide compounds 503B outsourcing facilities got a slightly longer runway but faced the same endpoint Who Can Still Legally Operate Legitimate ongoing options: 503B facilities may still compound for specific clinical needs (e.g., allergies to inactive ingredients, documented medical necessity) — but this is narrowly defined Personalized/combination compounds are still being debated legally Companies like Hims & Hers, Ro, and LifeMD faced pressure and adjusted their offerings accordingly What to Watch For Several compounders are challenging the FDA in court The situation is still evolving — check FDA.gov for current status Bottom line: Be cautious of any telehealth company still broadly offering compounded semaglutide — verify they're operating under a legitimate exemption.
Read full answer with sources →This is a fast-moving situation, so I want to be straightforward with you: What Happened The FDA declared the semaglutide shortage over (early 2025), which means compounding pharmacies largely must stop making copies of branded GLP-1s like Ozempic/Wegovy. Services That Have Adapted (as of my knowledge cutoff) Hims & Hers - Shifted toward personalized/combination formulations, though this is legally contested Ro (Body Program) - Moved toward brand-name prescriptions with manufacturer coupons LifeMD - Focuses on brand-name with savings programs Henry - Similar pivot to branded medications Honest Caveats This space changes weekly - companies' offerings shift rapidly due to ongoing litigation Some compounders are fighting the FDA ruling in court, so availability fluctuates "Personalized" compound formulations (added ingredients) exist in a legal gray area I'd recommend checking current reviews on Reddit's r/Ozempic or r/Semaglutide for real-time user experiences My Recommendation Call services directly and ask specifically what they currently offer, since their websites may lag behind actual availability. Would you like help thinking through what to ask them?
Read full answer with sources →The FDA has been cracking down on compounded versions of GLP-1 agonists like semaglutide and tirzepatide due to concerns about safety and efficacy. Here's a breakdown of what happened: FDA's Stance: The FDA has stated that when a drug is on the market and widely available, pharmacies are generally not permitted to compound that drug unless there's a specific shortage declared by the FDA. They have also expressed concerns about compounded versions that use different active ingredients (e.g., semaglutide sodium or semaglutide acetate instead of semaglutide free base, or tirzepatide instead of semaglutide) or are not manufactured under sterile conditions, posing potential risks. "Loopholes" and Concerns: Some compounding pharmacies have been creating these drugs by using different salt forms or related compounds that are not identical to the FDA-approved versions. The FDA's concern is that these compounded versions may not have the same safety and efficacy profiles as the original brand-name drugs, and there could be issues with purity, potency, and manufacturing quality. Enforcement Actions: The FDA has sent warning letters to compounding pharmacies and has taken steps to prevent the illegal distribution of these compounded drugs. Who is still operating legally? This is a complex and evolving situation, but here's a general overview of who is likely still operating legally and what to look for: FDA-Approved Brand-Name Medications: The most straightforward and legally sound way to access GLP-1 agonists is through FDA-approved brand-name medications prescribed by a doctor. These include: Ozempic (semaglutide) Wegovy (semaglutide) Rybelsus (oral semaglutide) Mounjaro (tirzepatide) Zepbound (tirzepatide) Victoza (liraglutide) Saxenda (liraglutide) Trulicity (dulaglutide) Byetta (exenatide) Bydureon (exenatide extended-release) You can obtain these by getting a prescription from your healthcare provider and filling it at a licensed pharmacy. Compounding Pharmacies Operating Within FDA Guidelines: Some compounding pharmacies may still be operating legally by adhering strictly to FDA regulations. This generally means: Only compounding if there is an FDA-declared shortage of the specific drug. Using active pharmaceutical ingredients (APIs) that are identical to the FDA-approved drug and not variations in salt forms or related compounds unless there's a clear clinical rationale and disclosure. Ensuring rigorous quality control and sterile manufacturing processes. It is challenging for consumers to definitively know which compounding pharmacies are consistently operating within these strict guidelines without specific FDA guidance or investigations into individual pharmacies. The landscape can change rapidly. What you should do as a consumer: Talk to Your Doctor: This is the most crucial step. Discuss your treatment goals and concerns with your healthcare provider. They can prescribe FDA-approved medications and guide you on the best and safest treatment options. Be Wary of "Compounded" Options Promising Significant Savings: While some compounded medications can be legitimate, be extra cautious when seeing advertisements for significantly cheaper compounded versions of popular, high-demand drugs like GLP-1s. This is often where the FDA's concerns lie. Verify the Pharmacy: If you are considering a compounded medication (which should ideally be discussed with your doctor first), ask your doctor if they can recommend a reputable compounding pharmacy. You can also research a pharmacy's accreditation and any reported FDA actions. Understand the Risks: Compounded drugs, especially those that deviate from FDA-approved formulations, may not have undergone the same rigorous testing for safety and efficacy. There's a higher risk of unexpected side effects, lack of effectiveness, or contamination. In summary, the FDA's focus is on ensuring the safety and efficacy of these powerful medications. The safest and most legally compliant way to access them is through FDA-approved brand-name versions obtained with a prescription from your doctor. Be very cautious with compounded alternatives and always prioritize a conversation with your healthcare provider.
Read full answer with sources →The FDA has ended the long-standing shortage of semaglutide and tirzepatide, triggering a crackdown on mass-compounded GLP-1s that are essentially copies of commercially available FDA-approved drugs; compounding is now legally permitted only for specific patients with documented medical needs requiring non-standard doses, forms, or unique indications that are not commercially available [1][2][3]. Companies that continue to mass-produce or market compounded GLP-1s as generic alternatives (such as Hims & Hers and similar telehealth/compounding pharmacies) are facing legal action, seizure, and injunctions for violating FDA policies and making misleading claims [5][7][8]. Who is still operating legally: Legitimate, state-licensed pharmacies and outsourcing facilities that compound GLP-1s strictly under Section 503A or 503B of the FD&C Act for individual patients with a bona fide need for non-standard formulations (e.g., non-standard doses, gummies, sprays, or added ingredients like B12 only if medically justified and not for mass marketing) [1][2][3]. No companies are legally permitted to routinely compound or mass-market GLP-1s that are essentially copies of Ozempic, Wegovy, Mounjaro, or Zepbound once the shortage has ended [3][4][10]. Recommended legal alternatives for patients: FDA-approved injectables: Ozempic and Wegovy (semaglutide) from Novo Nordisk, and Mounjaro and Zepbound (tirzepatide) from Eli Lilly are the only legally guaranteed, FDA-reviewed options for weight loss and diabetes [2][3][6]. Patients should obtain these through licensed prescribers and legitimate pharmacies (e.g., CVS, Walgreens, or local independent pharmacies) that verify supply and do not sell unapproved compounded versions. Brands to avoid for compounded GLP-1s: Hims & Hers, Ro, Brief, and other telehealth platforms that advertise mass-compounded semaglutide or tirzepatide as "generic" or "equivalent" to FDA-approved drugs are now operating illegally and may be subject to FDA enforcement [5][7][8]. The FDA has explicitly stated it will not take action only against compounders filling four or fewer prescriptions per month of essentially copied compounded drugs, but any mass production or marketing is prohibited [2]. Patients seeking weight-loss treatment should prioritize FDA-approved medications over compounded versions to ensure safety, efficacy, and regulatory compliance [3][6][9].
Read full answer with sources →